Cetrotide

Phase 1Peptide

EMD Serono

Cetrotide is one of 51 small molecule programs targeting Atherosclerosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AtherosclerosisActive, not recruiting

Ovarian Hyperstimulation SyndromeActive, not recruiting

AtherosclerosisPhase 1

Active, not recruiting

Ovarian Hyperstimulation SyndromePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Atherosclerosis

#DrugCompanyPhaseTrials

Avandia

Alnylam Pharmaceuticals

Phase 3

3 2

Estrace

Novo Nordisk

Phase 3

2 3

Depo-Provera

Pfizer

Phase 3

2 4

Colcrys

Alnylam Pharmaceuticals

Phase 3

1 5

Glucotrol

Pfizer

Phase 3

1 6

Actemra

Roche

Phase 3

1 7

Brilinta

AstraZeneca

Phase 3

1 8

Ilaris

Novartis

Phase 3

—9

Benicar

CCosette Pharmaceuticals, Inc.

Phase 3

2 10

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Stimulation4 trials

Synchronization of Follicle Wave Emergence and Ovarian Stimulation

Completed·UUniversity of Saskatchewan·Phase 4·NCT00439829·80 enrolled

Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI

Unknown status·ZZagazig University·N/A·NCT05751681·79 enrolled

A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation

Completed· EMD Serono logo

EMD Serono·Phase 4·NCT00298025·185 enrolled

Show 1 more trial

NATural Ovarian Stimulation

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT02892942·129 enrolled

Left Ventricular Dysfunction1 trial

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

Unknown status·TThe University of Texas at Arlington·Phase 4·NCT04671966·100 enrolled

ART1 trial

Delayed Start Versus Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase

Completed·—·Phase 3·NCT02333253·60 enrolled

Atherosclerosis1 trial

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

Completed·UUniversity of Colorado, Denver·Phase 1·NCT02042196·100 enrolled

Pregnancy1 trial

The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy

Unknown status·—·N/A·NCT04308343·120 enrolled

3 more indications

Treatment1 trial

Cetrotide Treatment Optimization

Terminated·BBart CJM Fauser·Phase 4·NCT00866034·617 enrolled

GnRH Antagonist1 trial

Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders

Completed·—·Phase 3·NCT04537078·90 enrolled

Ovarian Hyperstimulation Syndrome1 trial

Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)

Withdrawn·WWolfson Medical Center·Phase 1/2·NCT01109888

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Cetrotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cetrotide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cetrotide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMD Serono company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 1[1]
Company: EMD Serono

Cetrotide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Stimulation4 trials

Left Ventricular Dysfunction1 trial

ART1 trial

Atherosclerosis1 trial

Pregnancy1 trial

Treatment1 trial

GnRH Antagonist1 trial

Ovarian Hyperstimulation Syndrome1 trial

References

Drug Info

Quick Facts

Related News